Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Local directors in Bradford, having discussed the Elstree protocols, did not want interim heat-treated product that would only likely be available two or three months and preferred to wait until April when "a better product is promised"

  • Read more about Local directors in Bradford, having discussed the Elstree protocols, did not want interim heat-treated product that would only likely be available two or three months and preferred to wait until April when "a better product is promised"

In a Blood Transfusion Services meeting on 4th December 1984 it was said, theoretically, "heat-treated material was likely to be safer than non-treated material"

  • Read more about In a Blood Transfusion Services meeting on 4th December 1984 it was said, theoretically, "heat-treated material was likely to be safer than non-treated material"

In Bradford, in 1983, no cryoprecipitate was used for the treatment of patients with Haemophilia A; all treatment was with concentrates (NHS, Factorate and Kryobulin)

  • Read more about In Bradford, in 1983, no cryoprecipitate was used for the treatment of patients with Haemophilia A; all treatment was with concentrates (NHS, Factorate and Kryobulin)

In Bradford, in 1982, there was a move away from the use of cryoprecipitate to factor concentrates and the introduction of home treatment

  • Read more about In Bradford, in 1982, there was a move away from the use of cryoprecipitate to factor concentrates and the introduction of home treatment

In December 1984, Oxford Haemophilia Centre placed its first order for heat-treated concentrates

  • Read more about In December 1984, Oxford Haemophilia Centre placed its first order for heat-treated concentrates

The individual patient data shows people being treated with NHS and commercial concentrate and with more than one type of commercial concentrate.

  • Read more about The individual patient data shows people being treated with NHS and commercial concentrate and with more than one type of commercial concentrate.

In 1984 there were almost no cryoprecipitate; 1,919,162 units of NHS Factor 8; and 3,907,595 units of commercial concentrates.

  • Read more about In 1984 there were almost no cryoprecipitate; 1,919,162 units of NHS Factor 8; and 3,907,595 units of commercial concentrates.

There was almost no cryoprecipitate used for the treatment of Haemophilia A. 1,636,580 units of NHS Factor 8 were used; over 4.5 million units of commercial concentrates were used.

  • Read more about There was almost no cryoprecipitate used for the treatment of Haemophilia A. 1,636,580 units of NHS Factor 8 were used; over 4.5 million units of commercial concentrates were used.

Dr Rizza was in support of plans to set up an AIDS screening programme. The terms in which he wrote are instructive: "it is important that we act quickly to set up screening tests to detect the patients who might be at risk of developing the full blown condition."

  • Read more about Dr Rizza was in support of plans to set up an AIDS screening programme. The terms in which he wrote are instructive: "it is important that we act quickly to set up screening tests to detect the patients who might be at risk of developing the full blown condition."

Cardiff's Annual Return for 1984 recorded an increase in the use of cryoprecipitate, a greater increase in the amount of NHS concentrates used (1,704,313 units), and a reduction in the amount of commercial concentrates (861,677 units). The individual patient data filed with the 1984 return showed the treatment of a child born in 1971 with cryoprecipitate. The individual patient data filed with the 1984 return showed the treatment of a child born in 1983 with cryoprecipitate.

  • Read more about Cardiff's Annual Return for 1984 recorded an increase in the use of cryoprecipitate, a greater increase in the amount of NHS concentrates used (1,704,313 units), and a reduction in the amount of commercial concentrates (861,677 units). The individual patient data filed with the 1984 return showed the treatment of a child born in 1971 with cryoprecipitate. The individual patient data filed with the 1984 return showed the treatment of a child born in 1983 with cryoprecipitate.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 32
  • Page 33
  • Page 34
  • Page 35
  • Current page 36
  • Page 37
  • Page 38
  • Page 39
  • Page 40
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.